OBJECTIVES: The objective of the study is to investigate the cost-effectiveness of treating patients with psoriasis vulgaris in Sweden. METHODS: The cost-effectiveness analysis was performed by comparing effectiveness data obtained from an international multicentre study with the cost of the two products. RESULTS: The expected cost per percentage reduction in PASI in Sweden is SEK 15.78 for TCP twice daily, followed by SEK 8.98 for calcipotriol, and TCP once daily SEK 8.29 when comparing four weeks of treatment. Thus, TCP once daily is the most cost-effective treatment regime. In addition, when comparing current treatment practice (twice daily calcipotriol applied for 8 weeks) to the once daily application of the TCP for 4 weeks, it will reduce the treatment cost for psoriasis in Sweden by 46.2%. CONCLUSION: This study demonstrates that TCP applied once daily is both cost-effective and a cost-minimising treatment strategy, which offers psoriasis patients a convenient and highly effective treatment regime with a rapid onset of action.